Rani Therapeutics Holdings (RANI) Total Debt (2020 - 2025)
Rani Therapeutics Holdings (RANI) posted quarterly Total Debt of $13.5 million for Q3 2025, down 52.17% year-over-year from $28.3 million in Q3 2024, and down 21.43% quarter-over-quarter from $17.2 million in Q2 2025.
Rani Therapeutics Holdings (RANI) Total Debt (2020 - 2025) Analysis & Trends
Rani Therapeutics Holdings' Total Debt history runs 6 years deep, the most recent figure standing at $13.5 million for Q3 2025.
- In Q3 2025, Total Debt fell 52.17% year-over-year to $13.5 million; the TTM figure through Sep 2025 stood at $13.5 million (down 52.17% YoY), while the FY2024 annual figure was $24.6 million, down 16.23% from the prior year.
- Total Debt for Q3 2025 stood at $13.5 million, down from $17.2 million in the prior quarter.
- The five-year high for Total Debt was $29.5 million in Q2 2024, with the low at $30000.0 in Q2 2022.
- The 5-year median for Total Debt is $22.8 million (2024), against an average of $18.2 million.
- The sharpest annual moves came in 2022 and 2023: Total Debt tumbled 99.23% in 2022, then surged 97450.0% in 2023.
- Rani Therapeutics Holdings' Total Debt stood at $126000.0 in 2021, then surged by 23034.13% to $29.1 million in 2022, then advanced by 0.8% to $29.4 million in 2023, then dropped by 16.23% to $24.6 million in 2024, then sank by 45.0% to $13.5 million in 2025.
- Business Quant data shows RANI's Total Debt at $13.5 million in Q3 2025, $17.2 million in Q2 2025, and $20.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.34 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 770.36 Mn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 13.54 Mn |
| Jun 30, 2025 | 17.23 Mn |
| Mar 31, 2025 | 20.92 Mn |
| Dec 31, 2024 | 24.61 Mn |
| Sep 30, 2024 | 28.31 Mn |
| Jun 30, 2024 | 29.50 Mn |
| Mar 31, 2024 | 29.44 Mn |
| Dec 31, 2023 | 29.38 Mn |
| Sep 30, 2023 | 29.32 Mn |
| Jun 30, 2023 | 29.27 Mn |
| Mar 31, 2023 | 29.21 Mn |
| Dec 31, 2022 | 29.15 Mn |
| Sep 30, 2022 | 14.15 Mn |
| Jun 30, 2022 | 30,000.00 |
| Mar 31, 2022 | 140,000.00 |
| Dec 31, 2021 | 126,000.00 |
| Sep 30, 2021 | 290,000.00 |
| Jun 30, 2021 | 3.88 Mn |
| Dec 31, 2020 | 2.56 Mn |